SAFETY DATA SHEET

ViraPack Transfection Kit, Part Number 200488

Section 1. Identification

Product identifier : ViraPack Transfection Kit, Part Number 200488
Part no. (chemical kit) : 200488
Part no. :
- ViraPack Transfection Kit Solution 1 200488-51
- ViraPack Transfection Kit Solution 2 200488-52
- ViraPack Transfection Kit Solution 3 200488-53
- pCMV ß-Gal Control Plasmid 200388-54

Relevant identified uses of the substance or mixture and uses advised against

Material uses : Analytical reagent.
- ViraPack Transfection Kit Solution 1 5 ml
- ViraPack Transfection Kit Solution 2 25 ml
- ViraPack Transfection Kit Solution 3 40 ml
- pCMV ß-Gal Control Plasmid 0.04 ml (40 µg 1 µg/µl)

Supplier/Manufacturer : Agilent Technologies Australia Pty Ltd
679 Springvale Road
Mulgrave
Victoria 3170, Australia
1800 802 402

Emergency telephone number (with hours of operation) : CHEMTREC®: +(61)-290372994

Section 2. Hazard(s) identification

Classification of the substance or mixture
ViraPack Transfection Kit
Solution 1

SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2A
H319

ViraPack Transfection Kit Solution 1
- Percentage of the mixture consisting of ingredient(s) of unknown acute dermal toxicity: 30 - 60%
- Percentage of the mixture consisting of ingredient(s) of unknown acute inhalation toxicity: 30 - 60%
- Percentage of the mixture consisting of ingredient(s) of unknown acute oral toxicity: 30 - 60%

ViraPack Transfection Kit Solution 2
- Percentage of the mixture consisting of ingredient(s) of unknown acute dermal toxicity: 1 - 10%
- Percentage of the mixture consisting of ingredient(s) of unknown acute inhalation toxicity: 1 - 10%
- Percentage of the mixture consisting of ingredient(s) of unknown acute oral toxicity: 1 - 10%

ViraPack Transfection Kit Solution 3
- Percentage of the mixture consisting of ingredient(s) of unknown acute dermal toxicity: > 60%
- Percentage of the mixture consisting of ingredient(s) of unknown acute inhalation toxicity: > 60%
- Percentage of the mixture consisting of ingredient(s) of unknown acute oral toxicity: > 60%

ViraPack Transfection Kit Solution 2
- Percentage of the mixture consisting of ingredient(s) of unknown hazards to the aquatic environment: 1.1%

ViraPack Transfection Kit Solution 3
- Percentage of the mixture consisting of ingredient(s) of unknown hazards to the aquatic environment: 98.8%
Section 2. Hazard(s) identification

GHS label elements

Hazard pictograms :

ViraPack Transfection Kit Solution 1

Signal word :

ViraPack Transfection Kit Solution 1
WARNING
ViraPack Transfection Kit Solution 2
No signal word.
ViraPack Transfection Kit Solution 3
No signal word.
pCMV ß-Gal Control Plasmid
No signal word.

Hazard statements :

ViraPack Transfection Kit Solution 1
H319 - Causes serious eye irritation.
ViraPack Transfection Kit Solution 2
No known significant effects or critical hazards.
ViraPack Transfection Kit Solution 3
No known significant effects or critical hazards.
pCMV ß-Gal Control Plasmid
No known significant effects or critical hazards.

Precautionary statements

Prevention :

ViraPack Transfection Kit Solution 1
P280 - Wear eye or face protection.
P264 - Wash hands thoroughly after handling.
Not applicable.
ViraPack Transfection Kit Solution 2
Not applicable.
ViraPack Transfection Kit Solution 3
Not applicable.
pCMV ß-Gal Control Plasmid
Not applicable.

Response :

ViraPack Transfection Kit Solution 1
P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P337 + P313 - If eye irritation persists: Get medical attention.
Not applicable.
ViraPack Transfection Kit Solution 2
Not applicable.
ViraPack Transfection Kit Solution 3
Not applicable.
pCMV ß-Gal Control Plasmid
Not applicable.

Storage :

ViraPack Transfection Kit Solution 1
Not applicable.
ViraPack Transfection Kit Solution 2
Not applicable.
ViraPack Transfection Kit Solution 3
Not applicable.
pCMV ß-Gal Control Plasmid
Not applicable.

Disposal :

ViraPack Transfection Kit Solution 1
Not applicable.
ViraPack Transfection Kit Solution 2
Not applicable.
ViraPack Transfection Kit Solution 3
Not applicable.
pCMV ß-Gal Control Plasmid
Not applicable.

Supplemental label elements

Date of issue/Date of revision : 08/04/2019
Date of previous issue : 30/03/2017
Version : 5
Section 2. Hazard(s) identification

Additional warning phrases:
- ViraPack Transfection Kit Solution 1: Not applicable.
- ViraPack Transfection Kit Solution 2: Not applicable.
- ViraPack Transfection Kit Solution 3: Not applicable.
- pCMV ß-Gal Control Plasmid: Not applicable.

Other hazards which do not result in classification:
- ViraPack Transfection Kit Solution 1: None known.
- ViraPack Transfection Kit Solution 2: None known.
- ViraPack Transfection Kit Solution 3: None known.
- pCMV ß-Gal Control Plasmid: None known.

Section 3. Composition and ingredient information

<table>
<thead>
<tr>
<th>Substance/mixture</th>
<th>Ingredient name</th>
<th>CAS number/other identifiers</th>
</tr>
</thead>
<tbody>
<tr>
<td>ViraPack Transfection Kit Solution 1</td>
<td>Calcium chloride (CaCl₂), dihydrate</td>
<td>≥30 - ≤60 10035-04-8</td>
</tr>
<tr>
<td>ViraPack Transfection Kit Solution 3</td>
<td>Ethanol</td>
<td>≤3 64-17-5</td>
</tr>
</tbody>
</table>

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment and hence require reporting in this section.

Occupational exposure limits, if available, are listed in Section 8.

Section 4. First aid measures

Description of necessary first aid measures

Eye contact:
- ViraPack Transfection Kit Solution 1: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.
- ViraPack Transfection Kit Solution 2: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
- ViraPack Transfection Kit Solution 3: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
- pCMV ß-Gal Control Plasmid: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
<table>
<thead>
<tr>
<th><strong>Section 4. First aid measures</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inhalation</strong></td>
</tr>
<tr>
<td><strong>ViraPack Transfection Kit Solution 1</strong></td>
</tr>
<tr>
<td><strong>ViraPack Transfection Kit Solution 2</strong></td>
</tr>
<tr>
<td><strong>ViraPack Transfection Kit Solution 3</strong></td>
</tr>
<tr>
<td><strong>pCMV β-Gal Control Plasmid</strong></td>
</tr>
<tr>
<td><strong>Skin contact</strong></td>
</tr>
<tr>
<td><strong>ViraPack Transfection Kit Solution 1</strong></td>
</tr>
<tr>
<td><strong>ViraPack Transfection Kit Solution 2</strong></td>
</tr>
<tr>
<td><strong>ViraPack Transfection Kit Solution 3</strong></td>
</tr>
<tr>
<td><strong>pCMV β-Gal Control Plasmid</strong></td>
</tr>
<tr>
<td><strong>Ingestion</strong></td>
</tr>
<tr>
<td><strong>ViraPack Transfection Kit Solution 1</strong></td>
</tr>
<tr>
<td><strong>ViraPack Transfection Kit Solution 2</strong></td>
</tr>
<tr>
<td><strong>ViraPack Transfection Kit</strong></td>
</tr>
</tbody>
</table>
Solution 3

pCMV β-Gal Control Plasmid

ViraPack Transfection Kit, Part Number 200488

Section 4. First aid measures

Air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

Most important symptoms/effects, acute and delayed

Potential acute health effects

Eye contact

ViraPack Transfection Kit Solution 1

ViraPack Transfection Kit Solution 2

ViraPack Transfection Kit Solution 3

pCMV β-Gal Control Plasmid

No known significant effects or critical hazards.

ViraPack Transfection Kit Solution 1

ViraPack Transfection Kit Solution 2

ViraPack Transfection Kit Solution 3

pCMV β-Gal Control Plasmid

No known significant effects or critical hazards.

Inhalation

ViraPack Transfection Kit Solution 1

ViraPack Transfection Kit Solution 2

ViraPack Transfection Kit Solution 3

pCMV β-Gal Control Plasmid

No known significant effects or critical hazards.

Skin contact

ViraPack Transfection Kit Solution 1

ViraPack Transfection Kit Solution 2

ViraPack Transfection Kit Solution 3

pCMV β-Gal Control Plasmid

No known significant effects or critical hazards.

Ingestion

ViraPack Transfection Kit Solution 1

ViraPack Transfection Kit Solution 2

ViraPack Transfection Kit Solution 3

pCMV β-Gal Control Plasmid

No known significant effects or critical hazards.

Over-exposure signs/symptoms

Eye contact

ViraPack Transfection Kit Solution 1

ViraPack Transfection Kit Solution 2

ViraPack Transfection Kit Solution 3

pCMV β-Gal Control Plasmid

Adverse symptoms may include the following:

- Pain or irritation
- Watering
- Redness

No specific data.

No specific data.

No specific data.
Section 4. First aid measures

Protection of first-aiders:

ViraPack Transfection Kit Solution 1
No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.

ViraPack Transfection Kit Solution 2
No action shall be taken involving any personal risk or without suitable training.

ViraPack Transfection Kit Solution 3
No action shall be taken involving any personal risk or without suitable training.

pCMV ß-Gal Control Plasmid
No action shall be taken involving any personal risk or without suitable training.

Notes to physician:

ViraPack Transfection Kit Solution 1
Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.

ViraPack Transfection Kit Solution 2
In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

ViraPack Transfection Kit Solution 3
In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

pCMV ß-Gal Control Plasmid
Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.

Specific treatments:

ViraPack Transfection Kit Solution 1
No specific treatment.

ViraPack Transfection Kit Solution 2
No specific treatment.

ViraPack Transfection Kit Solution 3
No specific treatment.

pCMV ß-Gal Control Plasmid
No specific treatment.

Indication of immediate medical attention and special treatment needed, if necessary

Inhalation:

ViraPack Transfection Kit Solution 1
No specific data.

ViraPack Transfection Kit Solution 2
No specific data.

ViraPack Transfection Kit Solution 3
No specific data.

pCMV ß-Gal Control Plasmid
No specific data.

Ingestion:

ViraPack Transfection Kit Solution 1
No specific data.

ViraPack Transfection Kit Solution 2
No specific data.

ViraPack Transfection Kit Solution 3
No specific data.

pCMV ß-Gal Control Plasmid
No specific data.

Skin contact:

ViraPack Transfection Kit Solution 1
No specific data.

ViraPack Transfection Kit Solution 2
No specific data.

ViraPack Transfection Kit Solution 3
No specific data.

pCMV ß-Gal Control Plasmid
No specific data.

See toxicological information (Section 11)
## Section 5. Firefighting measures

### Extinguishing media

<table>
<thead>
<tr>
<th>Suitable extinguishing media</th>
<th>ViraPack Transfection Kit Solution 1</th>
<th>ViraPack Transfection Kit Solution 2</th>
<th>ViraPack Transfection Kit Solution 3</th>
<th>pCMV β-Gal Control Plasmid</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Use an extinguishing agent suitable for the surrounding fire.</td>
<td>Use an extinguishing agent suitable for the surrounding fire.</td>
<td>Use an extinguishing agent suitable for the surrounding fire.</td>
<td>Use an extinguishing agent suitable for the surrounding fire.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Unsuitable extinguishing media</th>
<th>ViraPack Transfection Kit Solution 1</th>
<th>ViraPack Transfection Kit Solution 2</th>
<th>ViraPack Transfection Kit Solution 3</th>
<th>pCMV β-Gal Control Plasmid</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>None known.</td>
<td>None known.</td>
<td>None known.</td>
<td>None known.</td>
</tr>
</tbody>
</table>

### Specific hazards arising from the chemical

<table>
<thead>
<tr>
<th>ViraPack Transfection Kit Solution 1</th>
<th>In a fire or if heated, a pressure increase will occur and the container may burst.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ViraPack Transfection Kit Solution 2</td>
<td>In a fire or if heated, a pressure increase will occur and the container may burst.</td>
</tr>
<tr>
<td>ViraPack Transfection Kit Solution 3</td>
<td>In a fire or if heated, a pressure increase will occur and the container may burst.</td>
</tr>
<tr>
<td>pCMV β-Gal Control Plasmid</td>
<td>In a fire or if heated, a pressure increase will occur and the container may burst.</td>
</tr>
</tbody>
</table>

### Hazardous thermal decomposition products

<table>
<thead>
<tr>
<th>ViraPack Transfection Kit Solution 1</th>
<th>Decomposition products may include the following materials: halogenated compounds metal oxide/oxides</th>
</tr>
</thead>
<tbody>
<tr>
<td>ViraPack Transfection Kit Solution 2</td>
<td>Decomposition products may include the following materials: carbon dioxide carbon monoxide nitrogen oxides sulfur oxides halogenated compounds metal oxide/oxides</td>
</tr>
<tr>
<td>ViraPack Transfection Kit Solution 3</td>
<td>Decomposition products may include the following materials: carbon dioxide carbon monoxide nitrogen oxides sulfur oxides halogenated compounds metal oxide/oxides</td>
</tr>
<tr>
<td>pCMV β-Gal Control Plasmid</td>
<td>No specific data.</td>
</tr>
</tbody>
</table>

### Special protective actions for fire-fighters

<table>
<thead>
<tr>
<th>ViraPack Transfection Kit Solution 1</th>
<th>Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ViraPack Transfection Kit Solution 2</td>
<td>Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.</td>
</tr>
<tr>
<td>ViraPack Transfection Kit Solution 3</td>
<td>Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.</td>
</tr>
<tr>
<td>pCMV β-Gal Control Plasmid</td>
<td>Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.</td>
</tr>
</tbody>
</table>
**Section 5. Firefighting measures**

**Special protective equipment for fire-fighters**

- **ViraPack Transfection Kit Solution 1**
  - Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

- **ViraPack Transfection Kit Solution 2**
  - Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

- **ViraPack Transfection Kit Solution 3**
  - Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

- **pCMV β-Gal Control Plasmid**
  - Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

**Section 6. Accidental release measures**

**Personal precautions, protective equipment and emergency procedures**

**For non-emergency personnel**

- **ViraPack Transfection Kit Solution 1**
  - No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.

- **ViraPack Transfection Kit Solution 2**
  - No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.

- **ViraPack Transfection Kit Solution 3**
  - No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.

- **pCMV β-Gal Control Plasmid**
  - No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.

**For emergency responders**

- **ViraPack Transfection Kit Solution 1**
  - If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

- **ViraPack Transfection Kit Solution 2**
  - If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

- **ViraPack Transfection Kit Solution 3**
  - If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

- **pCMV β-Gal Control Plasmid**
  - If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
Section 6. Accidental release measures

Environmental precautions:

ViraPack Transfection Kit Solution 1
Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

ViraPack Transfection Kit Solution 2
Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

ViraPack Transfection Kit Solution 3
Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

pCMV β-Gal Control Plasmid
Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

Methods and material for containment and cleaning up

Methods for cleaning up:

ViraPack Transfection Kit Solution 1
Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

ViraPack Transfection Kit Solution 2
Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

ViraPack Transfection Kit Solution 3
Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

pCMV β-Gal Control Plasmid
Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

Section 7. Handling and storage

Precautions for safe handling

Protective measures:

ViraPack Transfection Kit Solution 1
Put on appropriate personal protective equipment (see Section 8). Do not ingest. Avoid contact with eyes, skin and clothing. Avoid breathing vapour or mist. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.

ViraPack Transfection Kit Solution 2

ViraPack Transfection Kit Solution 3

Put on appropriate personal protective equipment (see Section 8).
### Section 7. Handling and storage

#### Advice on general occupational hygiene

<table>
<thead>
<tr>
<th>Material</th>
<th>Advice</th>
</tr>
</thead>
<tbody>
<tr>
<td>ViraPack Transfection Kit Solution 1</td>
<td>Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.</td>
</tr>
<tr>
<td>ViraPack Transfection Kit Solution 2</td>
<td>Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.</td>
</tr>
<tr>
<td>ViraPack Transfection Kit Solution 3</td>
<td>Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.</td>
</tr>
<tr>
<td>pCMV ß-Gal Control Plasmid</td>
<td>Put on appropriate personal protective equipment (see Section 8).</td>
</tr>
</tbody>
</table>

#### Conditions for safe storage, including any incompatibilities

<table>
<thead>
<tr>
<th>Material</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>ViraPack Transfection Kit Solution 1</td>
<td>Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.</td>
</tr>
<tr>
<td>ViraPack Transfection Kit Solution 2</td>
<td>Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.</td>
</tr>
<tr>
<td>Virapack Transfection Kit Solution 3</td>
<td>Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.</td>
</tr>
</tbody>
</table>
Section 7. Handling and storage

pCMV β-Gal Control Plasmid

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Section 8. Exposure controls and personal protection

Control parameters

Occupational exposure limits

<table>
<thead>
<tr>
<th>Ingredient name</th>
<th>Exposure limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Virapack Transfection Kit Solution 3</td>
<td>Safe Work Australia (Australia, 4/2018).</td>
</tr>
<tr>
<td>Ethanol</td>
<td>TWA: 1880 mg/m³ 8 hours.</td>
</tr>
<tr>
<td></td>
<td>TWA: 1000 ppm 8 hours.</td>
</tr>
</tbody>
</table>

Appropriate engineering controls

Environmental exposure controls

- Good general ventilation should be sufficient to control worker exposure to airborne contaminants.
- Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Individual protection measures

Hygiene measures

- Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

- Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

Skin protection

Hand protection

- Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

Body protection

- Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection

- Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection

- Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.
### Section 9. Physical and chemical properties

#### Appearance

| Physical state | ViraPack Transfection Kit Solution 1 | Liquid. |
|               | ViraPack Transfection Kit Solution 2 | Liquid. |
|               | ViraPack Transfection Kit Solution 3 | Not available. |
|               | pCMV ß-Gal Control Plasmid | Not available. |

| Colour | ViraPack Transfection Kit Solution 1 | Not available. |
|        | ViraPack Transfection Kit Solution 2 | Not available. |
|        | ViraPack Transfection Kit Solution 3 | Not available. |
|        | pCMV ß-Gal Control Plasmid | Not available. |

| Odour | ViraPack Transfection Kit Solution 1 | Not available. |
|       | ViraPack Transfection Kit Solution 2 | Not available. |
|       | ViraPack Transfection Kit Solution 3 | Not available. |
|       | pCMV ß-Gal Control Plasmid | Not available. |

| Odour threshold | ViraPack Transfection Kit Solution 1 | Not available. |
|                | ViraPack Transfection Kit Solution 2 | Not available. |
|                | ViraPack Transfection Kit Solution 3 | Not available. |
|                | pCMV ß-Gal Control Plasmid | Not available. |

| pH | ViraPack Transfection Kit Solution 1 | Not available. |
|    | ViraPack Transfection Kit Solution 2 | 6.95 |
|    | ViraPack Transfection Kit Solution 3 | Not available. |
|    | pCMV ß-Gal Control Plasmid | Not available. |

| Melting point | ViraPack Transfection Kit Solution 1 | Not available. |
|              | ViraPack Transfection Kit Solution 2 | 0°C (32°F) |
|              | ViraPack Transfection Kit Solution 3 | Not available. |
|              | pCMV ß-Gal Control Plasmid | 0°C (32°F) |

| Boiling point | ViraPack Transfection Kit Solution 1 | Not available. |
|              | ViraPack Transfection Kit Solution 2 | 100°C (212°F) |
|              | ViraPack Transfection Kit Solution 3 | Not available. |
|              | pCMV ß-Gal Control Plasmid | 100°C (212°F) |

| Flash point | ViraPack Transfection Kit Solution 1 | Not available. |
|            | ViraPack Transfection Kit Solution 2 | Not available. |
|            | ViraPack Transfection Kit Solution 3 | Not available. |
|            | pCMV ß-Gal Control Plasmid | Not available. |
Section 9. Physical and chemical properties

**Evaporation rate**
- ViraPack Transfection Kit Solution 1: Not available.
- ViraPack Transfection Kit Solution 2: Not available.
- Virapack Transfection Kit Solution 3: Not available.
- pCMV ß-Gal Control Plasmid: Not available.

**Flammability (solid, gas)**
- ViraPack Transfection Kit Solution 1: Not applicable.
- ViraPack Transfection Kit Solution 2: Not applicable.
- Virapack Transfection Kit Solution 3: Not applicable.
- pCMV ß-Gal Control Plasmid: Not applicable.

**Lower and upper explosive (flammable) limits**
- ViraPack Transfection Kit Solution 1: Not available.
- ViraPack Transfection Kit Solution 2: Not available.
- Virapack Transfection Kit Solution 3: Not available.
- pCMV ß-Gal Control Plasmid: Not available.

**Vapour pressure**
- ViraPack Transfection Kit Solution 1: Not available.
- ViraPack Transfection Kit Solution 2: Not available.
- Virapack Transfection Kit Solution 3: Not available.
- pCMV ß-Gal Control Plasmid: Not available.

**Vapour density**
- ViraPack Transfection Kit Solution 1: Not available.
- ViraPack Transfection Kit Solution 2: Not available.
- Virapack Transfection Kit Solution 3: Not available.
- pCMV ß-Gal Control Plasmid: Not available.

**Relative density**
- ViraPack Transfection Kit Solution 1: Not available.
- ViraPack Transfection Kit Solution 2: Not available.
- Virapack Transfection Kit Solution 3: Not available.
- pCMV ß-Gal Control Plasmid: Not available.

**Solubility**
- ViraPack Transfection Kit Solution 1: Soluble in the following materials: cold water and hot water.
- ViraPack Transfection Kit Solution 2: Easily soluble in the following materials: cold water and hot water.
- Virapack Transfection Kit Solution 3: Easily soluble in the following materials: cold water and hot water.
- pCMV ß-Gal Control Plasmid: Not applicable.

**Partition coefficient: n-octanol/water**
- ViraPack Transfection Kit Solution 1: Not available.
- ViraPack Transfection Kit Solution 2: Not available.
- Virapack Transfection Kit Solution 3: Not available.
- pCMV ß-Gal Control Plasmid: Not available.
**Section 9. Physical and chemical properties**

**Auto-ignition temperature**
- ViraPack Transfection Kit Solution 1: Not available.
- ViraPack Transfection Kit Solution 2: Not available.
- Virapack Transfection Kit Solution 3: Not available.
- pCMV ß-Gal Control Plasmid: Not available.

**Decomposition temperature**
- ViraPack Transfection Kit Solution 1: Not available.
- ViraPack Transfection Kit Solution 2: Not available.
- Virapack Transfection Kit Solution 3: Not available.
- pCMV ß-Gal Control Plasmid: Not available.

**Viscosity**
- ViraPack Transfection Kit Solution 1: Not available.
- ViraPack Transfection Kit Solution 2: Not available.
- Virapack Transfection Kit Solution 3: Not available.
- pCMV ß-Gal Control Plasmid: Not available.

**Section 10. Stability and reactivity**

**Reactivity**
- ViraPack Transfection Kit Solution 1: No specific test data related to reactivity available for this product or its ingredients.
- ViraPack Transfection Kit Solution 2: No specific test data related to reactivity available for this product or its ingredients.
- Virapack Transfection Kit Solution 3: No specific test data related to reactivity available for this product or its ingredients.
- pCMV ß-Gal Control Plasmid: No specific test data related to reactivity available for this product or its ingredients.

**Chemical stability**
- ViraPack Transfection Kit Solution 1: The product is stable.
- ViraPack Transfection Kit Solution 2: The product is stable.
- Virapack Transfection Kit Solution 3: The product is stable.
- pCMV ß-Gal Control Plasmid: The product is stable.

**Possibility of hazardous reactions**
- ViraPack Transfection Kit Solution 1: Under normal conditions of storage and use, hazardous reactions will not occur.
- ViraPack Transfection Kit Solution 2: Under normal conditions of storage and use, hazardous reactions will not occur.
- Virapack Transfection Kit Solution 3: Under normal conditions of storage and use, hazardous reactions will not occur.
- pCMV ß-Gal Control Plasmid: Under normal conditions of storage and use, hazardous reactions will not occur.

**Conditions to avoid**
- ViraPack Transfection Kit Solution 1: No specific data.
- ViraPack Transfection Kit Solution 2: No specific data.
- Virapack Transfection Kit Solution 3: No specific data.
- pCMV ß-Gal Control Plasmid: No specific data.
Section 10. Stability and reactivity

**Incompatible materials**
- ViraPack Transfection Kit Solution 1
- ViraPack Transfection Kit Solution 2
- Virapack Transfection Kit Solution 3
- pCMV β-Gal Control Plasmid

May react or be incompatible with oxidising materials.

**Hazardous decomposition products**
- ViraPack Transfection Kit Solution 1
- ViraPack Transfection Kit Solution 2
- Virapack Transfection Kit Solution 3
- pCMV β-Gal Control Plasmid

Under normal conditions of storage and use, hazardous decomposition products should not be produced.

May react or be incompatible with oxidising materials.

Section 11. Toxicological information

**Information on toxicological effects**

**Acute toxicity**

<table>
<thead>
<tr>
<th>Product/ingredient name</th>
<th>Result</th>
<th>Species</th>
<th>Dose</th>
<th>Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>ViraPack Transfection Kit Solution 3</td>
<td>LC50 Inhalation Vapour</td>
<td>Rat</td>
<td>124700 mg/m³</td>
<td>4 hours</td>
</tr>
<tr>
<td>Ethanol</td>
<td>LD50 Oral</td>
<td>Rat</td>
<td>7 g/kg</td>
<td>-</td>
</tr>
</tbody>
</table>

**Irritation/Corrosion**

<table>
<thead>
<tr>
<th>Product/ingredient name</th>
<th>Result</th>
<th>Species</th>
<th>Score</th>
<th>Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>ViraPack Transfection Kit Solution 3</td>
<td>Eyes - Mild irritant</td>
<td>Rabbit</td>
<td>-</td>
<td>24 hours 500 milligrams</td>
</tr>
<tr>
<td>Ethanol</td>
<td>Eyes - Moderate irritant</td>
<td>Rabbit</td>
<td>-</td>
<td>0.066666667 minutes 100 milligrams</td>
</tr>
<tr>
<td></td>
<td>Eyes - Moderate irritant</td>
<td>Rabbit</td>
<td>-</td>
<td>100 microliters</td>
</tr>
<tr>
<td></td>
<td>Skin - Mild irritant</td>
<td>Rabbit</td>
<td>-</td>
<td>400 milligrams</td>
</tr>
<tr>
<td></td>
<td>Skin - Moderate irritant</td>
<td>Rabbit</td>
<td>-</td>
<td>24 hours 20 milligrams</td>
</tr>
</tbody>
</table>

**Sensitisation**
Not available.

**Mutagenicity**

**Conclusion/Summary**: Not available.

**Carcinogenicity**

**Conclusion/Summary**: Not available.

**Reproductive toxicity**

**Conclusion/Summary**: Not available.

**Teratogenicity**

**Conclusion/Summary**: Not available.

**Specific target organ toxicity (single exposure)**

**Date of issue/Date of revision**: 08/04/2019

**Date of previous issue**: 30/03/2017

**Version**: 5
Section 11. Toxicological information

Not available.

**Specific target organ toxicity (repeated exposure)**
Not available.

**Aspiration hazard**
Not available.

**Information on likely routes of exposure**

<table>
<thead>
<tr>
<th>Product</th>
<th>Routes of entry anticipated: Oral, Dermal, Inhalation.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ViraPack Transfection Kit Solution 1</td>
<td>Routes of entry anticipated: Oral, Dermal, Inhalation.</td>
</tr>
<tr>
<td>ViraPack Transfection Kit Solution 2</td>
<td>Routes of entry anticipated: Oral, Dermal, Inhalation.</td>
</tr>
<tr>
<td>Virapack Transfection Kit Solution 3</td>
<td>Routes of entry anticipated: Oral, Dermal, Inhalation.</td>
</tr>
<tr>
<td>pCMV ß-Gal Control Plasmid</td>
<td>Not available.</td>
</tr>
</tbody>
</table>

**Potential acute health effects**

**Eye contact**

- **ViraPack Transfection Kit Solution 1**: Causes serious eye irritation.
- **ViraPack Transfection Kit Solution 2**: No known significant effects or critical hazards.
- **Virapack Transfection Kit Solution 3**: No known significant effects or critical hazards.
- **pCMV ß-Gal Control Plasmid**: No known significant effects or critical hazards.

**Inhalation**

- **ViraPack Transfection Kit Solution 1**: No known significant effects or critical hazards.
- **ViraPack Transfection Kit Solution 2**: No known significant effects or critical hazards.
- **Virapack Transfection Kit Solution 3**: No known significant effects or critical hazards.
- **pCMV ß-Gal Control Plasmid**: No known significant effects or critical hazards.

**Skin contact**

- **ViraPack Transfection Kit Solution 1**: No known significant effects or critical hazards.
- **ViraPack Transfection Kit Solution 2**: No known significant effects or critical hazards.
- **Virapack Transfection Kit Solution 3**: No known significant effects or critical hazards.
- **pCMV ß-Gal Control Plasmid**: No known significant effects or critical hazards.

**Ingestion**

- **ViraPack Transfection Kit Solution 1**: No known significant effects or critical hazards.
- **ViraPack Transfection Kit Solution 2**: No known significant effects or critical hazards.
- **Virapack Transfection Kit Solution 3**: No known significant effects or critical hazards.
- **pCMV ß-Gal Control Plasmid**: No known significant effects or critical hazards.

**Symptoms related to the physical, chemical and toxicological characteristics**

**Eye contact**

- **ViraPack Transfection Kit Solution 1**: Pain or irritation, watering, redness
- **ViraPack Transfection Kit Solution 2**: No specific data.
- **Virapack Transfection Kit Solution 3**: No specific data.

**pCMV ß-Gal Control Plasmid**: No specific data.
# Section 11. Toxicological information

**Inhalation**
- ViraPack Transfection Kit Solution 1: No specific data.
- ViraPack Transfection Kit Solution 2: No specific data.
- ViraPack Transfection Kit Solution 3: No specific data.
- pCMV ß-Gal Control Plasmid: No specific data.

**Skin contact**
- ViraPack Transfection Kit Solution 1: No specific data.
- ViraPack Transfection Kit Solution 2: No specific data.
- ViraPack Transfection Kit Solution 3: No specific data.
- pCMV ß-Gal Control Plasmid: No specific data.

**Ingestion**
- ViraPack Transfection Kit Solution 1: No specific data.
- ViraPack Transfection Kit Solution 2: No specific data.
- ViraPack Transfection Kit Solution 3: No specific data.
- pCMV ß-Gal Control Plasmid: No specific data.

## Delayed and immediate effects as well as chronic effects from short and long-term exposure

### Short term exposure

**Potential immediate effects**
- Not available.

**Potential delayed effects**
- Not available.

### Long term exposure

**Potential immediate effects**
- Not available.

**Potential delayed effects**
- Not available.

### Potential chronic health effects

**General**
- ViraPack Transfection Kit Solution 1: No known significant effects or critical hazards.
- ViraPack Transfection Kit Solution 2: No known significant effects or critical hazards.
- ViraPack Transfection Kit Solution 3: No known significant effects or critical hazards.
- pCMV ß-Gal Control Plasmid: No known significant effects or critical hazards.

**Carcinogenicity**
- ViraPack Transfection Kit Solution 1: No known significant effects or critical hazards.
- ViraPack Transfection Kit Solution 2: No known significant effects or critical hazards.
- ViraPack Transfection Kit Solution 3: No known significant effects or critical hazards.
- pCMV ß-Gal Control Plasmid: No known significant effects or critical hazards.

**Mutagenicity**
- ViraPack Transfection Kit Solution 1: No known significant effects or critical hazards.
- ViraPack Transfection Kit Solution 2: No known significant effects or critical hazards.
- ViraPack Transfection Kit Solution 3: No known significant effects or critical hazards.
- pCMV ß-Gal Control Plasmid: No known significant effects or critical hazards.
Section 11. Toxicological information

**Teratogenicity**
- ViraPack Transfection Kit Solution 1: No known significant effects or critical hazards.
- ViraPack Transfection Kit Solution 2: No known significant effects or critical hazards.
- ViraPack Transfection Kit Solution 3: No known significant effects or critical hazards.
- pCMV β-Gal Control Plasmid: No known significant effects or critical hazards.

**Developmental effects**
- ViraPack Transfection Kit Solution 1: No known significant effects or critical hazards.
- ViraPack Transfection Kit Solution 2: No known significant effects or critical hazards.
- ViraPack Transfection Kit Solution 3: No known significant effects or critical hazards.
- pCMV β-Gal Control Plasmid: No known significant effects or critical hazards.

**Fertility effects**
- ViraPack Transfection Kit Solution 1: No known significant effects or critical hazards.
- ViraPack Transfection Kit Solution 2: No known significant effects or critical hazards.
- ViraPack Transfection Kit Solution 3: No known significant effects or critical hazards.
- pCMV β-Gal Control Plasmid: No known significant effects or critical hazards.

**Numerical measures of toxicity**

**Acute toxicity estimates**

<table>
<thead>
<tr>
<th>Product/ingredient name</th>
<th>Oral (mg/kg)</th>
<th>Dermal (mg/kg)</th>
<th>Inhalation (gases) (ppm)</th>
<th>Inhalation (vapours) (mg/l)</th>
<th>Inhalation (dusts and mists) (mg/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ViraPack Transfection Kit Solution 3</td>
<td>7000</td>
<td>N/A</td>
<td>N/A</td>
<td>124.7</td>
<td>N/A</td>
</tr>
<tr>
<td>Ethanol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Section 12. Ecological information

**Toxicity**

<table>
<thead>
<tr>
<th>Product/ingredient name</th>
<th>Result</th>
<th>Species</th>
<th>Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>ViraPack Transfection Kit Solution 1 Calcium chloride (CaCl2), dihydrate</td>
<td>Acute EC50 2900 mg/l Fresh water</td>
<td>Algae</td>
<td>72 hours</td>
</tr>
<tr>
<td></td>
<td>Acute NOEC 2000 mg/l Fresh water</td>
<td>Daphnia</td>
<td>48 hours</td>
</tr>
<tr>
<td></td>
<td>Acute EC50 17.921 mg/l Marine water</td>
<td>Algae - Ulva pertusa</td>
<td>96 hours</td>
</tr>
<tr>
<td></td>
<td>Acute EC50 2000 μg/l Fresh water</td>
<td>Daphnia - Daphnia magna</td>
<td>48 hours</td>
</tr>
<tr>
<td></td>
<td>Acute LC50 25500 μg/l Marine water</td>
<td>Crustaceans - Artemia franciscana - Larvae</td>
<td>48 hours</td>
</tr>
<tr>
<td></td>
<td>Acute LC50 42000 μg/l Fresh water</td>
<td>Fish - Oncorhynchus mykiss</td>
<td>4 days</td>
</tr>
<tr>
<td></td>
<td>Chronic NOEC 4.995 mg/l Marine water</td>
<td>Algae - Ulva pertusa</td>
<td>96 hours</td>
</tr>
<tr>
<td></td>
<td>Chronic NOEC 100 ul/L Fresh water</td>
<td>Daphnia - Daphnia magna - Neonate</td>
<td>21 days</td>
</tr>
<tr>
<td></td>
<td>Chronic NOEC 0.375 ul/L Fresh water</td>
<td>Fish - Gambusia holbrooki - Larvae</td>
<td>12 weeks</td>
</tr>
<tr>
<td>ViraPack Transfection Kit Solution 3 Ethanol</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Persistence and degradability
Section 12. Ecological information

<table>
<thead>
<tr>
<th>Product/ingredient name</th>
<th>Aquatic half-life</th>
<th>Photolysis</th>
<th>Biodegradability</th>
</tr>
</thead>
<tbody>
<tr>
<td>ViraPack Transfection Kit Solution 3</td>
<td>-</td>
<td>-</td>
<td>Readily</td>
</tr>
<tr>
<td>Ethanol</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

**Bioaccumulative potential**

<table>
<thead>
<tr>
<th>Product/ingredient name</th>
<th>LogP&lt;sub&gt;ow&lt;/sub&gt;</th>
<th>BCF</th>
<th>Potential</th>
</tr>
</thead>
<tbody>
<tr>
<td>ViraPack Transfection Kit Solution 3</td>
<td>Ethanol</td>
<td>-0.35</td>
<td>0.5</td>
</tr>
</tbody>
</table>

**Mobility in soil**

- **Soil/water partition coefficient (K<sub>oc</sub>)**: Not available.

**Other adverse effects**: No known significant effects or critical hazards.

Section 13. Disposal considerations

**Disposal methods**: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

Section 14. Transport information

**ADG / IMDG / IATA**: Not regulated as Dangerous Goods according to the ADG Code.

**Special precautions for user**: Transport within user’s premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

**Transport in bulk according to Annex II of Marpol and the IBC Code**: Not available.

Section 15. Regulatory information

**Standard Uniform Schedule of Medicine and Poisons**: Not regulated.

**Model Work Health and Safety Regulations - Scheduled Substances**: No listed substance

**International regulations**

- **Chemical Weapon Convention List Schedules I, II & III Chemicals**: Not listed.

Date of issue/Date of revision: 08/04/2019
Date of previous issue: 30/03/2017
Version: 5
Section 15. Regulatory information

Stockholm Convention on Persistent Organic Pollutants
Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)
Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals
Not listed.

Inventory list

<table>
<thead>
<tr>
<th>Country</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>Not determined.</td>
</tr>
<tr>
<td>Canada</td>
<td>Not determined.</td>
</tr>
<tr>
<td>China</td>
<td>Not determined.</td>
</tr>
<tr>
<td>Europe</td>
<td>Not determined.</td>
</tr>
<tr>
<td>Japan</td>
<td>Japan inventory (ENCS): Not determined.</td>
</tr>
<tr>
<td></td>
<td>Japan inventory (ISHL): Not determined.</td>
</tr>
<tr>
<td>New Zealand</td>
<td>Not determined.</td>
</tr>
<tr>
<td>Philippines</td>
<td>Not determined.</td>
</tr>
<tr>
<td>Republic of Korea</td>
<td>Not determined.</td>
</tr>
<tr>
<td>Taiwan</td>
<td>All components are listed or exempted.</td>
</tr>
<tr>
<td>Thailand</td>
<td>Not determined.</td>
</tr>
<tr>
<td>Turkey</td>
<td>Not determined.</td>
</tr>
<tr>
<td>United States</td>
<td>Not determined.</td>
</tr>
<tr>
<td>Viet Nam</td>
<td>Not determined.</td>
</tr>
</tbody>
</table>

Section 16. Any other relevant information

History

<table>
<thead>
<tr>
<th>Date of issue/Date of revision</th>
<th>08/04/2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of previous issue</td>
<td>30/03/2017</td>
</tr>
<tr>
<td>Version</td>
<td>5</td>
</tr>
</tbody>
</table>

Key to abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADG</td>
<td>Australian Dangerous Goods</td>
</tr>
<tr>
<td>ADR</td>
<td>The European Agreement concerning the International Carriage of Dangerous Goods by Road</td>
</tr>
<tr>
<td>ATE</td>
<td>Acute Toxicity Estimate</td>
</tr>
<tr>
<td>BCF</td>
<td>Bioconcentration Factor</td>
</tr>
<tr>
<td>GHS</td>
<td>Globally Harmonized System of Classification and Labelling of Chemicals</td>
</tr>
<tr>
<td>IATA</td>
<td>International Air Transport Association</td>
</tr>
<tr>
<td>IBC</td>
<td>Intermediate Bulk Container</td>
</tr>
<tr>
<td>IMDG</td>
<td>International Maritime Dangerous Goods</td>
</tr>
<tr>
<td>LogPow</td>
<td>Logarithm of the octanol/water partition coefficient</td>
</tr>
<tr>
<td>N/A</td>
<td>Not available</td>
</tr>
<tr>
<td>SUSMP</td>
<td>Standard Uniform Schedule of Medicine and Poisons</td>
</tr>
<tr>
<td>UN</td>
<td>United Nations</td>
</tr>
</tbody>
</table>

Procedure used to derive the classification

<table>
<thead>
<tr>
<th>Classification</th>
<th>Justification</th>
</tr>
</thead>
<tbody>
<tr>
<td>ViraPack Transfection Kit Solution 1</td>
<td>Calculation method</td>
</tr>
<tr>
<td>Eye Irrit. 2A, H319</td>
<td></td>
</tr>
</tbody>
</table>

References

Not available.

Notice to reader

Indicates information that has changed from previously issued version.
Section 16. Any other relevant information

Disclaimer: The information contained in this document is based on Agilent’s state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.